Parmax Pharma (BOM:540359) PB Ratio: (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540359 Parmax Pharma Ltd BOM:540359
39 GF Score
Price ₹102.92
GF Value ₹25.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Parmax Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-21), Parmax Pharma's share price is ₹102.92. Parmax Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was ₹-16.43. Hence, Parmax Pharma's PB Ratio of today is .

The historical rank and industry rank for Parmax Pharma's PB Ratio or its related term are showing as below:

During the past 13 years, Parmax Pharma's highest PB Ratio was 113.52. The lowest was 1.18. And the median was 2.33.

BOM:540359's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.86
* Ranked among companies with meaningful PB Ratio only.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Parmax Pharma was 8.70% per year. The lowest was -73.80% per year. And the median was 4.05% per year.

Back to Basics: PB Ratio


Parmax Pharma  (BOM:540359) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Parmax Pharma PB Ratio Related Terms


Parmax Pharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Parmax Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma PB Ratio Chart

Parmax Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 1.94 101.35 0.00 0.00

Parmax Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:540359 vs ZTS, UTHR: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parmax Pharma PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Parmax Pharma's PB Ratio falls into.


BOM:540359
39GF Score
Parmax Pharma Ltd BOM:540359
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parmax Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Parmax Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=102.92/-16.434
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Parmax Pharma (BOM:540359) Overvalued in 2026?

Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued. The current stock price of ₹102.92 is trading 302.7% above its estimated GF Value™ of ₹25.56. GuruFocus considers Parmax Pharma to be Significantly Overvalued.

Key valuation signals for BOM:540359:

  • PB Ratio:
  • GF Value™: ₹25.56 vs. price of ₹102.92 (302.7% above fair value)
  • GF Score™: 39/100 with 8 warning signs

No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Parmax Pharma Business Description

Address Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its Core Segments: Anti-infectives, Analgesics & anti-inflammatory, Cardiovascular APIs, General oral formulations (tablets, capsules) Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
39GF Score

Get the complete analysis for BOM:540359

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹102.92
Price
₹25.56
GF Value